Trastuzumab deruxtecan targets HER2 on tumor cells, is internalized, and releases deruxtecan, which inhibits topoisomerase I to induce DNA damage and apoptosis; killing depends on HER2-mediated delivery (with possible bystander effect), not on expression of topoisomerase I itself.